Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-03-29
2011-03-29
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S237100
Reexamination Certificate
active
07914794
ABSTRACT:
Group Bstreptococcus(GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.
REFERENCES:
patent: 5225331 (1993-07-01), Lacroix et al.
patent: 5302386 (1994-04-01), Kasper et al.
patent: 5472696 (1995-12-01), Boyle et al.
patent: 5595740 (1997-01-01), Brady
patent: 5648241 (1997-07-01), Michel et al.
patent: 5679768 (1997-10-01), Briles et al.
patent: 5721339 (1998-02-01), Boyle et al.
patent: 5843713 (1998-12-01), Yoshida et al.
patent: 5869064 (1999-02-01), Lindahl et al.
patent: 5908629 (1999-06-01), Michel et al.
patent: 6248329 (2001-06-01), Chandrashekar et al.
patent: 6420135 (2002-07-01), Kunsch et al.
patent: 2007/0275004 (2007-11-01), Rioux et al.
patent: 1054971 (2006-12-01), None
patent: WO 94/21685 (1994-09-01), None
patent: 98/18930 (1998-05-01), None
patent: WO98/18931 (1998-05-01), None
patent: 99/42588 (1999-08-01), None
patent: WO 00/06736 (2000-02-01), None
patent: 01/32882 (2001-05-01), None
patent: 03/068813 (2003-08-01), None
Bowie et al (Science, 1990, 247:1306-1310).
Burgess et al (J. of Cell Bio. 111:2129-2138, 1990).
Lazar et al. (Molecular and Cellular Biology, 1988, 8:1247-1252).
Bork (Genome Research, 2000,10:398-400).
Ellis, Chapter 29 of Vaccines, Plotkin, et al. (eds) WB Saunders, Philadelphia, 1988, pp. 568-574.
Kil et al. (Infect. Immun., 62:2440-2449, 1994).
UniProtKB/TrEMBL entry Q54524, http://ca.expasy.org/cgi-bin
iceprot.pl/printable?ac=Q54524, accessed Aug. 14, 2006.
Colman, Res. Immunol., 145:33-36, 1994.
Abaza et al., J. Prot. Chem., 11:433-444, 1992.
Blythe et al., Prot. Sci., 14:246-248, 2005.
Accession No. JHO633, seq. in Legros et al.,Gene112(2):247-250, 1992, sequence alignment only.
Accession No. S53362, Guyonnet-Duperat et al.,Biochem J. 305:211-19, 1995, sequence alignment only.
Baltimore, R., et al., “Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group BStreptococci,” Journal of Immunology 118(2):673-78, Feb. 1977.
Carberry-Goh, et al., “Streptococcal Genetics,”American Society of Microbiology, Washington, D.C., pp. 22-24, 1987.
Ferrieri, P., et al., “Surface-localized protein antigens of group BStreptococci,”Reviews of Infectious Diseases 10(Suppl 2):S363-6, Jul.-Aug. 1988.
GenBank Database Accession No. AF026542, Oct. 15, 1997.
GenBank Database Accession No. AF062533, Feb. 11, 1999.
GenBank Database Accession No. L23843, Jan. 4, 1994.
GenBank Database Accession No. V52136, Oct. 23, 1998.
Heard, S., et al., “New phenotypic typing scheme for group BStreptococci,”Journal of Clinical Pathology 46(2):145-8, Feb. 1993.
Kil, K., et al., “Cloning and sequence analysis of a gene encoding a 67-kilodalton myosin-cross-reactive antigen ofStreptococcus pyogenesreveals its similarity with class II major histocompatibility antigens,”Infection and Immunity 62(6):2440-9, Jun. 1994.
Lachenauer, C., et al., “A protective surface protein from type V group BStreptococcishares N-terminal sequence homology with the alpha C protein,”Infection and Immunity 64(10):4255-60, Oct. 1996.
Lachenauer, C., et al., “Cloning and expression inEscherichia coliof a protective surface protein from type V group BStreptococci,” Advances in Experimental Medicine and Biology 418:615-8, Dec. 1997.
Lancefield, R., et al., “Multiple mouse-protective antibodies directed against group BStreptococci. Special reference to antibodies effective against protein antigens,”Journal of Experimental Medicine 142(1):165-79, Jul. 1, 1975.
Linden, V., “Mouse-protective effect of rabbit anti-R-protein antibodies against group BStreptococcitype II carrying R-protein. Lack of effect on type III carrying R-protein,”Acta Pathol. Microbial. Immunol. Scand.[B] 91(2):145-51, Apr. 1983.
Maeland, J., et al., “Streptococcus agalactiaebeta gene and gene product variations,”Journal of Medical Microbiology 46(12):999-1005, Dec. 1997.
Michel, J., et al., “Cloned alpha and beta C-protein antigens of group BStreptococcielicit protective immunity,”Infection and Immunity59(6):2023-8, Jun. 1991.
Michel, J., et al., “Genetics and Molecular Biology ofStreptococci, Lactococci and Enterococci,” American Society for Microbiology, pp. 214-218, 1991.
Michel, J., et al., “Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group BStreptococci,” Proceedings of the National Academy of Science U S A 89(21):10060-4, Nov. 1, 1992.
Pincus, S., et al., “Group B streptococcal opacity variants,”Journal of Bacteriology 174(11):3739-49, Jun. 1992.
Salasia, S., et al., “Phase variation inStreptococciof serological group B. Characteristic properties of isolates from human and bovine infection,”APMIS 102(12):925-30, Dec. 1994.
Sequence Alignment for SEQ ID No. 16, of US Pat. T,344,199, Hofler et al., filed Jul. 1997.
SPTREMBL Accession No. Q54524, Nov. 1, 1994.
Swiss-Prot. Accession No. Q54524, EMBL Accession No. U09352, Nov. 1996.
Wastfelt, M., et al., “Identification of a family of streptococcal surface proteins with extremely repetitive structure,”Journal of Biological Chemistry 271(31):18892-7, Aug. 2, 1996.
Gravekamp et al., “Variation in repeat number within the alpha C protein of group BStreptococcialters antigenicity and protective epitopes,”Infection and Immunity 64(9):3576-83, 1996.
Baltimore, R., et al., “Mouse protection test for group BStreptococcustype III,”Journal of Infectious Disease 140(1):81-8, Jul. 1979.
Brodeur, B., et al., “Identification of group B streptococcal Sip protein, which elicits cross-protective immunity,”Infection and Immunity 68(10):5610-8, Oct. 2000.
Kasper, D., et al., “Immune response to type III group B streptococcal polysaccharido-tetanus toxoid conjugate vaccine,”Journal of Clinical Investigation 98(10):2308-14, Nov. 15, 1996.
Kogan, G., et al., “Structural and immunochemical characterization of the type VIII group BStreptococcuscapsular polysaccharide,”Journal of Biological Chemistry 271(15):8786-90, Apr. 12, 1996.
Larsson, C., et al., “Experimental vaccination against group BStreptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha,”Infection and Immunity 64(9):3518-23, Sep. 1996.
Larsson, C., et al., “Protection against experimental infection with group BStreptococcusby immunization with a bivalent protein vaccine,”Vaccine, 17(5):454-8, Feb. 5, 1999.
Madoff, L., et al., “Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes,”Journal of Clinical Investigation 94(1):286-92, Jul. 1994.
Martin, D., et al., “Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein,”Infection and Immunity 70(9):4897-901, Sep. 2002.
Noya, F., et al., “Prevention of group B streptococcal infection,”Infectious Disease Clinics of North America 6(1):41-55, Mar. 1992.
Paoletti, L., et al., “Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine,”Infection and Immunity 62(8):3236-43, Aug. 1994.
Park, Hee-Myung, et al., “Identification of Lactoferrin-binding Proteins inStreptococcus dysgalactiaesubsp.DysgalactiaeandStreptococcus agalactiaeIsolated from Cows with Mastitis,”FEMS Microbiology Letters, 207:87 90, 2002.
Reinscheid, D., et al., “Identification and molecular analysis of PcsB, a protein required for cell wal
Boyer Martine
Brodeur Bernard R.
Charlebois Isabelle
Hamel Josee
Martin Denis
Gangle Brian J
ID Biomedical Corporation
Minnifield N. M
Seed IP Law Group PLLC
LandOfFree
Group B streptococcus antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group B streptococcus antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group B streptococcus antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643202